# Combatting virulent gut bacteria by inhibiting the biosynthesis of a two-component lanthipeptide toxin

## TL;DR

Scientists developed inhibitors to block a toxic peptide produced by gut bacteria, which could lead to new treatments for a severe form of liver disease.

## Contribution

The study introduces small molecule inhibitors that block the maturation of a two-component toxin in pathogenic gut bacteria.

## Key findings

- Inhibitors block toxin maturation at low micromolar to nanomolar concentrations.
- Inhibitors reduce hemolytic activity and cytolysin levels without affecting cell growth.
- Crystal structure insights reveal substrate recognition and enzyme activation mechanisms.

## Abstract

The enterococcal cytolysin is a toxic, two-component ribosomally synthesized and post-translationally modified peptide (RiPP) produced by pathogenic Enterococcus faecalis. Cytolysin-producing (C+) E. faecalis resides in the gut microbiome in a commensal role, but results in negative clinical outcomes in alcoholic hepatitis patients. To potentially combat cytolysin virulence, we report inhibitors of its maturation. An extracellular serine protease CylA that is essential for toxin activation is chosen as target. A series of α-aminopeptide boronic acids are designed and synthesized that block cytolysin maturation at low micromolar to nanomolar concentrations in vitro. A crystal structure of CylA provides insights into substrate recognition, autocatalytic activation of the enzyme, and toxin maturation. The inhibitors block hemolytic activity, reduce the amount of cytolysin, and attenuate expression of the cytolysin biosynthetic gene cluster without impeding cell growth. These studies provide a potential route to the development of treatments for cytolysin-induced disease states.

The enterococcal cytolysin is a two-component toxin that is responsible for a fatal form of alcoholic hepatitis. Here, authors used knowledge of the toxin’s biosynthesis to develop small molecule inhibitors of toxin production.